STAT3 and cancer: Several studies reported that inhibition of the STAT3 signaling pathway reduced the expression of cyclin D1 and enhanced the drug sensitivity of the cancer cells, including gastric carcinoma [131], cholangiocarcinoma [132], bladder cancer [133] and hepatocellular carcinoma [134].